Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Fingolimod derivative containing crown ether and di (2-methoxyethoxy) structure

A technology of structural formula and alkoxy group, which is applied in the field of drug synthesis and can solve problems such as limiting the application of the treatment of immune diseases

Active Publication Date: 2020-06-05
REVIVALLON BIOPHARMACEUTICAL CO LTD
View PDF10 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

In clinical studies, it was found that it can stimulate S1P at the same time 3 receptor, causing side effects of bradycardia, greatly limiting its application in the treatment of immune diseases

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Fingolimod derivative containing crown ether and di (2-methoxyethoxy) structure
  • Fingolimod derivative containing crown ether and di (2-methoxyethoxy) structure
  • Fingolimod derivative containing crown ether and di (2-methoxyethoxy) structure

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0032] Preparation of 1,8-bis(p-toluenesulfonate)-3,6-dioxoctane (2)

[0033] Add 16kg (400mol) sodium hydroxide and 80L water into the 400 reaction kettle to dissolve, then add 18.8L (140mol) triethylene glycol and 32L tetrahydrofuran into the reaction kettle, cool below 5°C, and drop 47.84kg (260mol ) p-toluenesulfonyl chloride, 50L tetrahydrofuran solution, after dropping, react at this temperature for 2h, pour into 240L ice water, filter with suction, wash with a small amount of water, and dry to obtain 58.64kg white crystalline powder with a yield of 91.4%. mp: 77-80°C, HPLC: 97%. TLC (petroleum ether:ethyl acetate=1:1, Rf=0.87). 1 HNMR (CDCl 3 ): δppm: 7.78 (d, 4H, J=10.4Hz, the benzene ring relies on the sulfonyl proton); 7.34 (d, 4H, J=11.6Hz, the benzene ring relies on the methyl proton); 4.129 (dd, 4H, J= 5.6Hz, close to the sulfonyl glycol proton); 3.64 (dd, 4H, J=5.6Hz, away from the sulfonyl glycol proton); 3.517 (s, 4H, a molecule of ethylene glycol proton in ...

Embodiment 2

[0035] Preparation of 3,4-benzo-12-crown-4-benzene (3)

[0036] Mix 2.2kg (20mol) catechol, 12.4kg (89.6mol) potassium carbonate and 300L DMF, stir for about 30min., heat up to 85-90°C, add 8-di(p-toluenesulfonate)-3 dropwise, Preparation of 6-dioxoctane (2) 40L of DMF solution of 9.17kg (20mol), dripping is finished within 1.5~2h, dripping is finished, reaction is 30min., TLC checks that reaction is complete (developing agent: sherwood oil: ethyl acetate = 1:1, Rf = 0.58). Suck out about 40L of the reaction solution, continue to repeat the above operation 3 to 5 times, filter with suction, evaporate the DMF to dryness under reduced pressure, dissolve the residue with 240L of ethyl acetate, filter with suction, evaporate under reduced pressure, and use petroleum ether:ethyl acetate for the residue= 1:1 for column chromatography. The solvent was recovered under reduced pressure, and the solid was recrystallized with isopropanol 1:2.5 (W / V) to obtain 1.376 kg of off-white powd...

Embodiment 3

[0043] 3. Preparation of 4-benzo-12-crown-α-chloroacetophenone (4)

[0044] Under ice cooling (0°C), 3,4-benzo-12-crown-4-benzene (18 g, 80.3 mmol) was dissolved in 200 mL of dry CH 2 Cl 2 In, add chloroacetyl chloride (9.1g, 80.3mmol), then slowly add AlCl 3 (16.1g, 120.5mmol), when AlCl 3 After all was added, it was naturally raised to room temperature and continued to stir for 2h. TLC (petroleum ether: ethyl acetate = 1:1, Rf = 0.52) detected that the raw material point disappeared, and the reaction solution was poured into ice water hydrochloric acid to decompose, the organic layer was separated, and the aqueous layer was washed with CH 2 Cl 2 Extracted 3 times, combined organic layers, washed to neutral, anhydrous Na 2 SO 4 After drying, filtering and concentrating, 22.6 g of the crude product was obtained as a pale yellow solid. , suction filtration, and ethanol recrystallization to obtain 19.2 g of slightly yellow to yellow crystalline powder, with a yield of 79%...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

A series of fingolimod derivatives containing crown ether or di (2-methoxyethoxy) structures are designed and synthesized by modifying the structure of an immunosuppressant fingolimod for treating multiple sclerosis on the market. The hypoglycemic effect of the target compound is evaluated through in-vivo animal experiments. Results show that the compounds including 1c-1e and Ic-Ie have a certaineffect of reducing blood sugar, and have application prospects in preparation of drugs for treating diabetes.

Description

[0001] The present invention relates to novel crown ether and fingolimod derivatives with bis(2-methoxyethoxy) structure, and also relates to the use of these compounds in medicines for treating diseases such as diabetes. technical field [0002] The invention relates to novel Fingolimod hydrochloride derivatives with a crown ether or bis(2-methoxyethoxy) structure and their preparation methods, belonging to the technical field of drug synthesis. The present invention provides new options for treating diabetes. [0003] technical background [0004] Fingolimod was originally the natural amino acid structure extracted from Cordyceps sinensis by Tetsuro Fujita, a professor of pharmacology at Kyoto University. The compound was originally studied as an immunosuppressant, but after further testing, Novartis Pharmaceuticals of Switzerland put away the transplant The idea of ​​the patient using an immunosuppressant drug because it did not exceed existing drugs. Interestingly, the c...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C07D323/00C07C213/08C07C217/72A61P3/10A61P35/00A61P25/28
CPCC07D323/00C07C217/72A61P3/10A61P35/00A61P25/28
Inventor 姜海业马晓莉马忠民
Owner REVIVALLON BIOPHARMACEUTICAL CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com